Search

Your search keyword '"Freise, Noemi"' showing total 14 results
Start Over Author "Freise, Noemi" Language english
14 results on '"Freise, Noemi"'

2. Percutaneous fractionated radiotherapy of the groin to eliminate lymphatic fistulas after vascular surgery

Author

Jazmati, Danny, Tamaskovics, Bálint, Hoff, Norman-Philipp, Homey, Bernhard, Bölke, Edwin, Boyomo, Belebenie, Garabet, Waseem, Haussmann, Jan, Budach, Wilfried, Neuwahl, Judith, Schelzig, Hubert, Corradini, Stefanie, van Griensven, Martijn, Fischer, Johannes, Knoefel, Wolfram Trudo, Pegani, John, Pedoto, Alessia, Antoch, Gerald, Kirchner, Julian, Lüdde, Tom, Freise, Noemi F., Feldt, Torsten, Jensen, Björn-Erik Ole, Keitel, Verena, and Matuschek, Christiane

Published
2023
Full Text
View/download PDF

4. Acute cardiac side effects after COVID-19 mRNA vaccination: a case series

Author

Freise, Noemi F., Kivel, Milena, Grebe, Olaf, Meyer, Christian, Wafaisade, Bahram, Peiper, Matthias, Zeus, Tobias, Schmidt, Jan, Neuwahl, Judith, Jazmati, Danny, Luedde, Tom, Bölke, Edwin, Feldt, Torsten, Jensen, Björn Erik Ole, Bode, Johannes, Keitel, Verena, Haussmann, Jan, Tamaskovics, Balint, Budach, Wilfried, Fischer, Johannes C., Knoefel, Wolfram Trudo, Schneider, Marion, Gerber, Peter Arne, Pedoto, Alessia, Häussinger, Dieter, van Griensven, Martijn, Rezazadeh, Amir, Flaig, Yechan, Kirchner, Julian, Antoch, Gerald, Schelzig, Hubert, and Matuschek, Christiane

Published
2022
Full Text
View/download PDF

5. Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection

Author

Fischer, Johannes C., Balz, Vera, Jazmati, Danny, Bölke, Edwin, Freise, Noemi F., Keitel, Verena, Feldt, Torsten, Jensen, Björn-Erik Ole, Bode, Johannes, Lüdde, Tom, Häussinger, Dieter, Adams, Ortwin, Schneider, E. Marion, Enczmann, Jürgen, Rox, Jutta M., Hermsen, Derik, Schulze-Bosse, Karin, Kindgen-Milles, Detlef, Knoefel, Wolfram Trudo, van Griensven, Martijn, Haussmann, Jan, Tamaskovics, Balint, Plettenberg, Christian, Scheckenbach, Kathrin, Corradini, Stefanie, Pedoto, Alessia, Maas, Kitti, Schmidt, Livia, Grebe, Olaf, Esposito, Irene, Ehrhardt, Anja, Peiper, Matthias, Buhren, Bettina Alexandra, Calles, Christian, Stöhr, Andreas, Gerber, Peter Arne, Lichtenberg, Artur, Schelzig, Hubert, Flaig, Yechan, Rezazadeh, Amir, Budach, Wilfried, and Matuschek, Christiane

Published
2022
Full Text
View/download PDF

6. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort

Author

Freise, Noemi F., Gliga, Smaranda, Fischer, Johannes, Lübke, Nadine, Lutterbeck, Matthias, Schöler, Miriam, Bölke, Edwin, Orth, Hans Martin, Feldt, Torsten, Roemmele, Christoph, Wilke, Dominik, Schneider, Jochen, Wille, Kai, Hohmann, Christian, Strauss, Richard, Hower, Martin, Ruf, Andreas, Schubert, Joerg, Isberner, Nora, Stecher, Melanie, Pilgram, Lisa, Vehreschild, Jörg J., Hanses, Frank, Luedde, Tom, and Jensen, Björn

Published
2022
Full Text
View/download PDF

7. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction

Author

Hoff, Norman-Philipp, Freise, Noemi F., Schmidt, Albrecht G., Firouzi-Memarpuri, Parnian, Reifenberger, Julia, Luedde, Tom, Bölke, Edwin, Meller, Stephan, Homey, Bernhard, Feldt, Torsten, Jensen, Björn Erik Ole, Keitel, Verena, Schmidt, Livia, Maas, Kitti, Haussmann, Jan, Tamaskovics, Balint, Budach, Wilfried, Fischer, Johannes C., Buhren, Bettina Alexandra, Knoefel, Wolfram Trudo, Schneider, Marion, Gerber, Peter Arne, Pedoto, Alessia, Häussinger, Dieter, Grebe, Olaf, van Griensven, Martijn, Braun, Stephan A., Salzmann, Stefan, Rezazadeh, Amir, and Matuschek, Christiane

Published
2021
Full Text
View/download PDF

9. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

Author

Fischer, Johannes C., Schmidt, Albrecht G., Bölke, Edwin, Uhrberg, Markus, Keitel, Verena, Feldt, Torsten, Jensen, Björn, Häussinger, Dieter, Adams, Ortwin, Schneider, E. Marion, Balz, Vera, Enczmann, Jürgen, Rox, Jutta, Hermsen, Derik, Schulze-Bosse, Karin, Kindgen-Milles, Detlef, Knoefel, Wolfram Trudo, van Griensven, Martijn, Haussmann, Jan, Tamaskovics, Balint, Plettenberg, Christian, Scheckenbach, Kathrin, Corradini, Stefanie, Pedoto, Alessia, Maas, Kitti, Schmidt, Livia, Grebe, Olaf, Esposito, Irene, Ehrhardt, Anja, Peiper, Matthias, Buhren, Bettina Alexandra, Calles, Christian, Stöhr, Andreas, Lichtenberg, Artur, Freise, Noemi F., Lutterbeck, Matthias, Rezazadeh, Amir, Budach, Wilfried, and Matuschek, Christiane

Published
2021
Full Text
View/download PDF

10. Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing

Author

Fischer, Johannes C., Schmidt, Albrecht G., Bölke, Edwin, Keitel, Verena, Feldt, Torsten, Jensen, Björn, Freise, Noemi F., Häussinger, Dieter, Schneider, E. Marion, Hermsen, Derik, Kindgen-Milles, Detlef, Knoefel, Wolfram Trudo, Haussmann, Jan, Tamaskovics, Balint, Plettenberg, Christian, Scheckenbach, Kathrin, Corradini, Stefanie, Rox, Jutta, Balz, Vera, Maas, Kitti, Schmidt, Livia, Grebe, Olaf, Ehrhardt, Anja, Gerber, Peter Arne, Peiper, Matthias, Buhren, Bettina Alexandra, Lichtenberg, Artur, Rezazadeh, Amir, Budach, Wilfried, and Matuschek, Christiane

Published
2021
Full Text
View/download PDF

11. Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing

Author

Fischer, Johannes C., Schmidt, Albrecht G., Bölke, Edwin, Keitel, Verena, Feldt, Torsten, Jensen, Björn, Freise, Noemi F., Häussinger, Dieter, Schneider, E. Marion, Hermsen, Derik, Kindgen-Milles, Detlef, Knoefel, Wolfram Trudo, Haussmann, Jan, Tamaskovics, Balint, Plettenberg, Christian, Scheckenbach, Kathrin, Corradini, Stefanie, Rox, Jutta, Balz, Vera, Maas, Kitti, Schmidt, Livia, Grebe, Olaf, Ehrhardt, Anja, Gerber, Peter Arne, Peiper, Matthias, Buhren, Bettina Alexandra, Lichtenberg, Artur, Rezazadeh, Amir, Budach, Wilfried, and Matuschek, Christiane

Published
2021
Full Text
View/download PDF

13. Conjugated bilirubin triggers anemia by inducing erythrocyte death

Author

Lang, Elisabeth, Gatidis, Sergios, Freise, Noemi F., Bock, Hans, Kubitz, Ralf, Lauermann, Christian, Orth, Hans Martin, Klindt, Caroline, Schuier, Maximilian, Keitel, Verena, Reich, Maria, Liu, Guilai, Schmidt, Sebastian, Xu, Haifeng C., Qadri, Syed M., Herebian, Diran, Pandyra, Aleksandra A., Mayatepek, Ertan, Gulbins, Erich, Lang, Florian, Häussinger, Dieter, Lang, Karl S., Föller, Michael, and Lang, Philipp A.

Published
2015
Full Text
View/download PDF

14. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.

Author

Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, Lutterbeck M, Freise NF, Schoeler D, Haas R, Dilthey A, Adams O, Walker A, Timm J, and Luedde T

Abstract

Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants., Methods: After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration., Findings: After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment., Interpretation: Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies., Funding: All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions., Competing Interests: BJ received honoraria for presentations from Gilead (Remdesivir) as well as Falk, Janssen-Cilag, MSD, BMS, Abbvie, ViiV, Gilead, Boehringer, Fresenius Medical Care (outside the submitted work) and served on advisory boards for ViiV, BMS, Gilead, Theratechnologies (outside the submitted work). VK received lecture fees from Abbvie, Falk, Albireo, Gilead (outside the submitted work). TF was PI for a Gilead clinical trial (Remdesivir) and served on Gilead advisory boards. All other authors declare no competing interests regarding this work., (© 2021 The Author(s).)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results